RSS   Newsletter   Contact   Advertise with us
Post Online Media

Juniper appoints Alicia Secor president and CEO

Alicia SecorJuniper Pharmaceuticals, Inc., a women's health therapeutics company, announced that it has appointed veteran healthcare executive Alicia Secor as its president and CEO, effective August 1, 2016.
Article continues below

READ MORE Juniper Networks appoints Terese Kemble as CHRO

Ms. Secor will also be appointed to the Board of Directors. Ms. Secor' brings more than 25 years' of leadership experience as a life sciences executive, with a track record in leading businesses and advancing products from clinical development through regulatory approval, commercialization, and global expansion across several therapeutic areas.

She joins Juniper from Zafgen, Inc., where she served as Chief Commercial Officer and played a key role in advancing the company to a Phase 3 pre-commercialization status.

Previously Ms. Secor served 15 years at Genzyme Corporation in diverse leadership roles, most recently as the Global General Manager for the Metabolic Disease Business.

Prior to Genzyme, Ms. Secor held positions at Alkermes in business development, at Centocor (a Johnson & Johnson Company) in clinical and commercial operations. She began her career at Pfizer as a hospital-based sales representative.

Ms. Secor received an M.B.A. from Northeastern University, and a B.S. in Healthcare Administration from the University of New Hampshire.

Ms. Secor succeeds Frank Condella, who announced his intent to retire as Juniper's President and CEO earlier this year.

Mr. Condella will remain on the Board as a non-executive director, and will consult to the Company for an interim period to ensure an orderly transition.

 LATEST MOVES FROM Massachusetts 


We use cookies to ensure that we give you the best experience on our website. Please allow cookies for fully-functioning website.

Allow Cookies Privacy Policy